Document Detail


Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
MedLine Citation:
PMID:  21948719     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients prescribed antiplatelet treatment to prevent recurrent acute myocardial infarction are often also given a selective serotonin reuptake inhibitor (SSRI) to treat coexisting depression. Use of either treatment may increase the risk of bleeding. We assessed the risk of bleeding among patients taking both medications following acute myocardial infarction.
METHODS: We conducted a retrospective cohort study using hospital discharge abstracts, physician billing information, medication reimbursement claims and demographic data from provincial health services administrative databases. We included patients 50 years of age or older who were discharged from hospital with antiplatelet therapy following acute myocardial infarction between January 1998 and March 2007. Patients were followed until admission to hospital due to a bleeding episode, admission to hospital due to recurrent acute myocardial infarction, death or the end of the study period.
RESULTS: The 27,058 patients in the cohort received the following medications at discharge: acetylsalicylic acid (ASA) (n = 14,426); clopidogrel (n = 2467), ASA and clopidogrel (n = 9475); ASA and an SSRI (n = 406); ASA, clopidogrel and an SSRI (n = 239); or clopidogrel and an SSRI (n = 45). Compared with ASA use alone, the combined use of an SSRI with antiplatelet therapy was associated with an increased risk of bleeding (ASA and SSRI: hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.08-1.87; ASA, clopidogrel and SSRI: HR 2.35, 95% CI 1.61-3.42). Compared with dual antiplatelet therapy alone (ASA and clopidogrel), combined use of an SSRI and dual antiplatelet therapy was associated with an increased risk of bleeding (HR 1.57, 95% CI 1.07-2.32).
INTERPRETATION: Patients taking an SSRI together with ASA or dual antiplatelet therapy following acute myocardial infarction were at increased risk of bleeding.
Authors:
Christopher Labos; Kaberi Dasgupta; Hacene Nedjar; Gustavo Turecki; Elham Rahme
Related Documents :
21807379 - Frontal subcortical ischemia is crucial for post stroke cognitive impairment.
19797149 - Prediction of response to cardiac resynchronization therapy using simple electrocardiog...
22115639 - Repair after myocardial infarction, between fantasy and reality the role of chemokines.
17452619 - Interventional electrophysiology and cardiac resynchronization therapy: delivering elec...
21176979 - Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical ...
22558579 - Gamma glutamyltransferase levels and its association with high sensitive c-reactive pro...
15561019 - Impaired endothelial function of the umbilical artery after fetal cardiac bypass.
12034149 - Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in pati...
17660059 - Intracerebral hemorrhage after thrombolytic therapy managed with ventricular drainage.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-09-26
Journal Detail:
Title:  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne     Volume:  183     ISSN:  1488-2329     ISO Abbreviation:  CMAJ     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-08     Completed Date:  2011-12-29     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  9711805     Medline TA:  CMAJ     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1835-43     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, McGill University, Montréal, Que.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / therapeutic use
Age Factors
Aged
Anemia / epidemiology
Angioplasty
Anticoagulants / therapeutic use
Antihypertensive Agents / therapeutic use
Aspirin / administration & dosage,  adverse effects
Canada / epidemiology
Citalopram / administration & dosage,  adverse effects
Cohort Studies
Drug Therapy, Combination
Female
Fluoxetine / administration & dosage,  adverse effects
Fluvoxamine / administration & dosage,  adverse effects
Heart Failure / epidemiology
Hemorrhage / chemically induced*,  epidemiology
Humans
Hypoglycemic Agents / therapeutic use
Male
Middle Aged
Myocardial Infarction / prevention & control*
Neoplasms / epidemiology
Paroxetine / administration & dosage,  adverse effects
Peptic Ulcer / epidemiology
Platelet Aggregation Inhibitors / administration & dosage,  adverse effects*
Recurrence / prevention & control
Renal Insufficiency / epidemiology
Retrospective Studies
Risk
Risk Factors
Serotonin Uptake Inhibitors / administration & dosage,  adverse effects*
Sertraline / administration & dosage,  adverse effects
Sex Factors
Ticlopidine / administration & dosage,  adverse effects,  analogs & derivatives
Grant Support
ID/Acronym/Agency:
//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Anticoagulants; 0/Antihypertensive Agents; 0/Hypoglycemic Agents; 0/Platelet Aggregation Inhibitors; 0/Serotonin Uptake Inhibitors; 50-78-2/Aspirin; 54739-18-3/Fluvoxamine; 54910-89-3/Fluoxetine; 55142-85-3/Ticlopidine; 59729-33-8/Citalopram; 61869-08-7/Paroxetine; 79617-96-2/Sertraline; A74586SNO7/clopidogrel
Comments/Corrections
Comment In:
CMAJ. 2011 Nov 8;183(16):1819-20   [PMID:  21969407 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contraction-induced Mmp13 and -14 expression by goat articular chondrocytes in collagen type I but n...
Next Document:  San Francisco Syncope Rule to predict short-term serious outcomes: a systematic review.